Inspire Pharmaceuticals, Inc. Provides Cystic Fibrosis Clinical Program Update

DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced an update on its clinical development program for denufosol tetrasodium for the treatment of cystic fibrosis (CF).